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ABSTRACT 
Although hepatitis E virus (HEV) is well known to cause acute hepatitis, there are reports showing that HEV 
may also be responsible for progression of acute to chronic hepatitis and liver cirrhosis in patients receiving or-
gan transplantation. In this study, we aimed to evaluate the prevalence of HEV in patients with kidney transplan-
tation. In this study, 110 patients with kidney transplantation were recruited, and anti-HEV IgG, creatinine, ala-
nine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and estimated glomer-
ular filtration rate (eGFR) in the first, third and sixth months after renal transplantation were measured. The 
mean serum anti-HEV IgG titers in the study participants was 1.36 (range 0.23 to 6.3). Twenty-three patients 
were found to be seropositive for HEV Ab defined as anti-HEV IgG titer > 1.1. The difference in liver and renal 
function tests (creatinine, eGFR, AST, ALT and ALP) at different intervals was not significant between patients 
with HEV Ab titers higher and lower than 1.1 (p > 0.05). However, an inverse correlation was observed between 
HEV Ab and eGFR values in the first (p = 0.047, r = -0.21), third (p = 0.04, r = -0.20) and sixth (p = 0.04, r = -
0.22) months after renal transplantation in patients with HEV Ab < 1.1 but not in the subgroup with HEV Ab > 
1.1. Also, a significant correlation between age and HEV Ab levels was found in the entire study population (p = 
0.001, r = 0.33). Our findings showed a high prevalence of seropositivity for anti-HEV IgG in patients receiving 
renal transplants. However, liver and renal functions were not found to be significantly different seropositive and 
seronegative patients by up to 6 months post-transplantation. 
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INTRODUCTION 
Hepatitis E, which is generally a self-
limiting disease, is caused by hepatitis E vi-
rus (HEV) (Balayan et al., 1983; Gupta and 
Smetana, 1957). This virus is a single-
stranded RNA virus without envelope, and is 
the only member of hepevirus from the 
Hepeviridae family (Kane et al., 1984; 
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Koonin et al., 1992). Distribution of HEV, 
which was previously known as non–A and 
non-B hepatitis, is mainly through water and 
feces, as is for viral hepatitis A (HAV) 
(Balayan et al., 1983; Khuroo, 1980). How-
ever, the transmission of HAV is much easi-
er with global distribution and causes more 
infections whereas HEV is more distributed 
in industrialized countries (Clemente-
Casares et al., 2003; Tang et al., 1991). The 
highest incidence of HEV infection is report-
ed in Asia, Africa, the Middle East and Cen-
tral America (Arankalle et al., 1988; Gupta 
and Smetana, 1957). Iran is one of the coun-
tries where hepatitis E is endemic, and sev-
eral HEV outbreaks have occurred so far 
(Alavian et al., 2009; Ghorbani et al., 2007). 
Although the transmission of hepatitis E vi-
rus has been reported from animal to human 
in developed countries, the major route of 
transmission is through the fecal-oral route. 
It has also been found that the consumption 
of undercooked meat or meat products is a 
major risk factor for HEV infection 
(Legrand-Abravanel et al., 2010). The most 
important diagnostic methods of HEV are 
PCR amplification of virus RNA or detection 
of Immunoglobulin M (IgM) antibodies 
against HEV. Currently, serological tests and 
qualitative and quantitative assessment of 
HEV RNA are considered as the gold stand-
ard tests for detection of HEV both for diag-
nostic and epidemiological purposes (Baylis 
et al., 2011; Khudyakov and Kamili, 2011; 
Takahashi et al., 2005). Several interventions 
such as elimination of chronic infection after 
reduction or discontinuation of immunosup-
pressive therapy, use of oral ribavirin and 
pegylated interferon have been suggested to 
be effective in the management of HEV in-
fection. However, there is as yet no proven 
treatment for acute or chronic hepatitis E in 
organ transplant patients (Aggarwal and 
Jameel, 2011; Chaillon et al., 2011; Kamar et 
al., 2011, 2014).  
Hepatitis E is responsible for acute hepa-
titis, and it was previously believed that 
HEV cannot be developed to chronic hepati-
tis. However, more recent reports show that 
HEV can lead to chronic hepatitis as well as 
liver cirrhosis in patients receiving organ 
transplants (Aggarwal, 2008; Koning et al., 
2015). It has been proposed that HEV does 
not usually lead to chronic hepatitis, except 
in patients who have solid organ transplanta-
tion or those whose immune system is sup-
pressed (Khuroo et al., 1980). Patients with 
organ transplantation are more susceptible to 
diseases caused by rare infectious viruses 
such as HEV; thus, differential diagnosis of 
pathogens such as hepatitis E virus in trans-
plant recipients is suggested to be applied 
according to the reports showing that there is 
a relatively rapid progression to cirrhosis and 
chronic hepatitis E in people who have had 
organ transplants (Ibarra et al., 1994; 
Stefanidis et al., 2004). Seroprevalence stud-
ies have shown that 6 to 15.6 % of kidney 
transplant patients are positive for anti-HEV 
IgG. In addition, studies have shown that 
HEV infection is commonly observed in pa-
tients with transplantation of solid organs 
such as the kidneys, liver and pancreas 
(Kamar et al., 2008; Khuroo, 2008). The fre-
quency of acute HEV infection in French pa-
tients with solid organ transplantation has 
been reported to be between 5 and 6.5 % 
(Legrand-Abravanel et al., 2011). Other fac-
tors that may lead to chronic HEV infection 
in patients with kidney transplantation in-
clude low lymphocyte (CD2, CD3 and CD4) 
count, low platelet count, young age < 52 
years and lymphopenia (Kamar et al., 2011; 
Legrand-Abravanel et al., 2011). 
Some studies have investigated the prev-
alence of hepatitis E in patients with kidney 
transplantation (Kamar et al., 2008; Legrand-
Abravanel et al., 2011). Given the high prev-
alence of transaminitis in the early stages af-
ter kidney transplantation and also uncertain-
ty about the role of hepatitis E, in this study, 
the serology of hepatitis E was evaluated in 
relation to hepatic and renal function indices 
in a group of patients with kidney transplan-
tation. 
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METHODS 
Data collection and population size calcula-
tion 
Demographic information of patients in-
cluding age, sex, and type of organ trans-
plant donor (living or cadaver) was collected 
based on medical history and questionnaire. 
All patients underwent standard triple im-
munosuppressive therapy with prednisone, 
cyclosporine and Mycophenolate mofetil. 
Samples were randomly selected from pa-
tients with kidney transplantation in the 
Montaserieh Hospital, Mashhad, Iran. Pa-
tients with transplant rejection or positive 
hepatitis B surface antigen (HbsAg), anti-
hepatitis C virus (HCV), and anti-cytome-
galovirus (CMV) IgM were excluded. Con-
sidering that the prevalence of HEV infec-
tion has been reported to be 7.7 % in previ-
ous studies (Kamar et al., 2008; Khuroo, 
2008; Legrand-Abravanel et al., 2011), the 
population size was calculated to be 110 pa-
tients using the following formula. 
N = (1.96)2×p(1-p)/d2= 
(1.96)2×0.077(1-0.077)/(0.05)2=110 
 
Biochemical assessment 
Serum levels of anti HEV IgG, creati-
nine, alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), alkaline phos-
phatase (ALP), and estimated glomerular fil-
tration rate (eGER) were measured at the 
first week, first month, third month, and 
sixth month post-transplantion. To determine 
anti-HEV IgG level, 2 mL of venous blood 
were taken and measured with ELISA after 
separating the serum from the blood. eGFR 
was calculated by the modification of diet in 
renal disease (MDRD) using the following 
equation: 
 
 
MDRD  = 175.0 × (Serum Creatinine)-1.154  
× (Age)-0.203 × 0.742 (if female)  
× 1.21 (if black) 
 
Statistical analysis 
Descriptive data are expressed as mean ± 
SD. Between-group comparisons were per-
formed using independent samples t-test (for 
normally distributed data) or Mann-Whitney 
U (for non-normally distributed data) test. 
Pearson (for normally distributed data) or 
Spearman (for non-normally distributed da-
ta) correlation coefficients test were used to 
evaluate the correlation between serology of 
hepatitis E with renal and hepatic function 
tests. All statistical analyses were performed 
using SPSS 15 software, and p-values less 
than 0.05 were considered as statistically 
significant. 
 
RESULTS 
Demographic information of the patients 
Among patients with renal transplanta-
tion admitted to the Montaserieh hospital, 
110 patients were randomly selected. The pa-
tients were enrolled after obtaining written 
informed consent. Of the enrolled partici-
pants, 59 patients (64.53 %) were male and 
51 (36.46 %) were female. The mean age of 
patients was 36.97 years, ranging between 15 
and 62 years.  
 
Assessment of biochemical markers 
Most of the patients (93.6 %) had hemo-
dialysis before receiving the transplanted 
kidney, and 35 patients had a history of 
blood transfusion (31.82 %). The mean se-
rum anti-HEV IgG titers in the study partici-
pants was 1.36 (range 0.23 to 6.3). Antibody 
titer for anti-HEV IgG was positive for 23 
patients (20.9 %), and negative in 86 
(78.18 %); in addition, antibody levels in 1 
case was on the borderline (0.91 %) that was 
further considered as seronegative. 
The results showed that there is no sig-
nificant difference in serum concentrations 
of creatinine, AST, ALT, and ALP at differ-
ent intervals between patients with HEV Ab 
titers higher and lower than 1.1. The mean 
value of serum ALP six months after trans-
plantation in seropositive and seronegative 
groups was 91.105 ± 69.251 and 57.237 ± 
85.101, respectively, that was not statistical-
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ly significant (p = 0.55). Mean serum creati-
nine level at the sixth month after transplan-
tation in the seropositive and seronegative 
groups were 1.52 ± 0.48 and 1.42 ± 0.39, re-
spectively, indicating that the difference be-
tween seropositive and seronegative groups 
was not significant (p = 0.33). In the group 
of patients with HEV Ab lower than 1.1, a 
negative correlation was found between the 
HEV Ab and the eGFR in the first month (p 
= 0.047, r = -0.21), the third month (p = 
0.04, r = -0.2) and the sixth month (p = 0.04, 
r = -0.22) after transplantation. However, no 
significant difference was observed in serum 
concentrations of creatinine, AST, ALT, and 
ALP at different intervals between patients 
with HEV Ab titers higher and lower than 
1.1. Moreover, a positive correlation was 
found between age and serum HCV Ab titers 
(p = 0.001, r = 0.33) in the entire study popu-
lation. Serum concentrations of creatinine, 
AST, ALT, ALP and eGFR at different in-
tervals in the seropositive and seronegative 
subjects are demonstrated in Table 1. 
Raw data are shown in Supplementary 
Table 1. 
 
 
 
Table 1: Values of renal and hepatic function indices at different intervals post-transplantation 
Variables HEV Ab > 1.1 HEV Ab < 1.1 p-value 
Cr (mg/dL) (1st week) 1.66 ± 0.49 0.45 ± 1.56 0.36 
Cr (mg/dL) (1st month) 1.61 ± 0.46 1.51 ± 0.43 0.32 
Cr (mg/dL) (3rd month) 1.53 ± 0.43 1.43 ± 0.38 0.29 
Cr (mg/dL) (6th month) 1.52 ± 0.48 1.42 ± 0.39 0.33 
AST (U/L) (1st week) 22.2 ± 8.35 22.55 ± 16.14 0.92 
AST (U/L) (1st month) 26.60 ± 11.03 22.57 ± 8.53 0.34 
AST (U/L) (3rd month) 23.65 ± 10.70 22.62 ± 7.88 0.60 
AST (U/L) (6th month) 24.08 ± 10.84 21.96 ± 8.73 0.32 
ALT (U/L) (1st week) 24.56 ± 12.50 30.26 ± 51.68 0.60 
ALT (U/L) (1st month) 29.91 ± 19.11 26.21 ± 19.02 0.41  
ALT (U/L) (3rd month) 32.8  ± 22.50 27.20 ± 21.66 0.34 
ALT (U/L) (6th month) 33.95 ± 27.43 28.49 ± 24.90 0.36 
ALP (U/L) (1st week) 248.04 ± 103.12 235.78 ± 89.63 0.57 
ALP (U/L) (1st month) 250.91 ± 103.36 239.41 ± 90.92 0.60 
ALP (U/L) (3rd month) 246.82 ± 102.70 235.17 ± 90.29 0.59 
ALP (U/L) (6th month) 251.69 ± 105.91 237.57 ± 101.85 0.55 
GFR (mL/min/1.73 m2) (1st week) 19.03 ± 62.50 ± 19.90 59.97 0.59 
GFR (mL/min/1.73 m2) (1st month) 19.20 ± 64.34 18.20 ± 61.65 0.55 
GFR (mL/min/1.73 m2) (3rd month) ± 18.36 67.37 ± 18.39 64.26 0.50 
GFR (mL/min/1.73 m2) (6th month) ± 21.20 69.63  55.07 ± 10.23 0.36 
HEV Ab: hepatitis E virus antibody; Cr: creatinine; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alka-
line phosphatase; GFR: glomerular filtration rate 
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DISCUSSION 
Kidney transplant recipients are known 
to be more susceptible to viral infections and 
show more severe clinical manifestation 
compared with healthy individuals (Quintana 
et al., 2005; Tang et al., 1991). More suscep-
tibility to viral infections in these patients is 
mainly due to immunosuppression caused by 
immunosuppressive drugs. Although hepati-
tis E was once thought to be a self-limited 
acute infection that rarely leads to chronic in-
fection, several recent investigations have 
reported chronic hepatitis and even cirrhosis 
related to hepatitis E in organ transplant re-
cipients (Ibarra et al., 1994; Tsega et al., 
1991; Yamashita et al., 2009).  
In a study in 2011, it was shown that 
there was no significant difference in serum 
ALT levels between patients with positive 
and negative anti-HEV IgG (Rostamzadeh 
Khameneh et al., 2011). It was also shown 
that there is no association between hepatitis 
E infection and increased serum levels of 
ALT. Hence, it was deduced that anti-HEV 
IgG antibodies is significantly higher in kid-
ney transplant patients compared with gen-
eral or hemodialysis population. In the men-
tioned study, of the total number of patients, 
28 patients were seropositive (30.8 %), 
whereas in our study, the prevalence of sero-
positivity for anti-HEV IgG was 20 %. 
Moreover, consistent with the above-
mentioned study, our findings showed that 
there was no significant association between 
serum ALT levels and anti-HEV IgG in se-
ropositive and seronegative groups. None-
theless, some studies have reported a posi-
tive association between the seroprevalence 
of HEV and blood transfusion in patients 
with organ transplantation (Arankalle et al., 
1995; Lynch et al., 1995; Sylvan, 1998). In a 
previous study on the epidemiology of anti-
HEV IgG antibodies in healthy blood donors 
of Iran, the prevalence of HEV infections 
was reported to be 7.7 % (Arabzadeh et al., 
2010; Hesamizadeh et al., 2016). It has also 
been shown that in a particular group of pa-
tients, such as patients undergoing hemodi-
alysis, HEV seroprevalence correlates with 
the prevalence of infections in the communi-
ty (Taremi et al., 2008). In different popula-
tions receiving kidney or liver transplanta-
tion, the HEV seroprevalence patients were 
reported between 1 % and 14.5 % (Koonin et 
al., 1992; Yamashita et al., 2009). Outbreak 
of hepatitis E also varies in different geo-
graphical areas. According to epidemiologi-
cal studies, low prevalence of anti-HEV IgG 
antibodies have been reported in countries 
such as Israel (8.2 %) and Turkey 8.3 %, but 
the prevalence of antibodies is rather high in 
countries such as Iraq (14.8 %), Saudi Ara-
bia (16.4 %) and Pakistan (17.5 %) (Kane et 
al., 1984; Krawczynski and Bradley, 1989; 
Yamashita et al., 2009). In a study that was 
conducted on 700 patients with organ trans-
plantation, 34 patients were found to be in-
fected with HEV one year after transplanta-
tion, and among them, 47 % were identified 
with chronic HEV and accordingly the annu-
al incidence of HEV was reported to be 
3.2 % (Lu et al., 2006).  
In conclusion, our findings in this study 
indicated that the prevalence of anti-HEV 
IgG is rather high (20 %) in Iranian patients 
with renal transplantation. However, it was 
shown that serum levels of creatinine, AST, 
ALT, and ALP, and eGFR at different inter-
vals is comparable between patients with 
HEV Ab titers higher and lower than 1.1. 
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